



GP1619
RECEIVED
MAR 12 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Xiaorong He) ATTORNEY DOCKET NO.: C-3409/1/US
SERIAL NO.: 10/008,223) GROUP ART UNIT: 1619
FILED: December 5, 2001) EXAMINER: Unknown
TITLE: RAPIDLY DISPERSING PHARMACEUTICAL COMPOSITION
DATE: March 6, 2003

3/13/03
upatch

CERTIFICATE OF MAILING

I hereby certify that this Information Disclosure Statement is being deposited with the United States Postal Service as First Class Mail in one package(s) addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on March 6, 2003.

Bernadette Y. Harper
Bernadette Y. Harper

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97(b)

Applicants hereby submit copies of patents, publications and/or other information of which they are aware and which may be related to the examination of this application, and in respect of which there may be a duty to disclose under 37 CFR § 1.56 and §§ 1.97 - 1.98 as supplemented by MPEP § 609. A list of all enclosed documents is provided in a Form PTO-1449, transmitted herewith. Presentation of documents listed on enclosed Form PTO-1449 is not an admission that any listed document is prior art under the Patent Statutes and the right is reserved to antedate any material described in the listed documents by a showing under 37 C.F.R. § 1.131 or otherwise.

This information disclosure statement is being filed within three months of the filing date of the above-cited patent application or prior to the mailing of a first Office

action on the merits, in accordance with 37 CFR § 1.97(b). Accordingly, Applicants respectfully request that the statement be considered by the Office in the course of prosecution of the application. No fee is believed payable; however, if it is determined that a fee is payable, please charge Deposit Account No. 19-1025.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR §1.97(g)), an admission that the information cited is or is considered to be material to patentability, or that no other material information exists.

Respectfully submitted,



David B. Fournier
Agent for Applicant
Registration No. 51,696
Tel. 847-581-5144

Address correspondence to:
Pharmacia Corporation
Global Patent Department
P.O. Box 1027
St. Louis, MO 63006

Enclosures:
Form PTO-1449
Copies of cited documents

Form PTO-1449
(Rev. 8-88)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket No.

Serial No.

C-3409/1/US

10/008,223

Applicant


He, X.

Filing Date

Group No.

December 5, 2001

1619

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initial*	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	5,037,657	Aug 06, 1991	Jones et al.	424	466	
	5,211,957	May 18, 1993	Hagemann et al.	424	466	
	5,223,264	Jun 29, 1993	Wheling et al.	424	466	
	5,424,075	Jun 13, 1995	Daher et al.	424	465	
	5,762,951	Jun 09, 1998	Maasz et al.	424	439	
	5,807,577	Sep 15, 1998	Ouali	424	466	

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	EP 0 396 335	Feb 02, 1994	EP	A61K	9/20		
	EP 0 476 696	Jun 21, 1995	EP	A61K	9/16		
	FR 2 793 685	Nov 24, 2000	FR	A61K	31/05		X
	1 595 220	Aug 12, 1981	GB	A61K	9/46		
	WO 95/03785	Feb 09, 1995	WO	A61K	9/00		

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

	Lieberman et al., ed. <i>Pharmaceutical Dosage Forms: Tablets</i> , Volume 1, 2 nd ed., Marcel Dekker, 34-36, 285-328. (1989).
	<i>United States Pharmacopeia</i> , 24 th ed., 2254-2304. (2000).
Examiner	Date Considered

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
MAR 12 2003
TECH CENTER 1600/2900